BofA Maintains Underperform on Amgen at $304 as Stock Trades Well Above Target
BofA Securities has kept an Underperform rating on Amgen with a $304 price target while the stock trades around $366.10 and close to its 52-week high. InvestingPro data indicates the shares are roughly fairly valued at current levels. The bank pointed to a series of pipeline catalysts stretching from 2026 into 2027 that will shape the company’s out…